Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening

Patrick Markt; Rasmus K Petersen; Esben N Flindt; Karsten Kristiansen; Johannes Kirchmair; Gudrun Spitzer; Simona Distinto; Daniela Schuster; Gerhard Wolber; Christian Laggner; Thierry Langer

doi:10.1021/jm800128k

Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening

Patrick Markt, Rasmus K Petersen, Esben N Flindt, Karsten Kristiansen, Johannes Kirchmair, Gudrun Spitzer, Simona Distinto, Daniela Schuster, Gerhard Wolber, Christian Laggner, Thierry Langer

59 Citations (Scopus)

Abstract

Peroxisome proliferator-activated receptors (PPARs) are important targets for drugs used in the treatment of atherosclerosis, dyslipidaemia, obesity, type 2 diabetes, and other diseases caused by abnormal regulation of the glucose and lipid metabolism. We applied a virtual screening workflow based on a combination of pharmacophore modeling with 3D shape and electrostatic similarity screening techniques to discover novel scaffolds for PPAR ligands. From the resulting 10 virtual screening hits, five tested positive in human PPAR ligand-binding domain (hPPAR-LBD) transactivation assays and showed affinities for PPAR in a competitive binding assay. Compounds 5, 7, and 8 were identified as PPAR-alpha agonists, whereas compounds 2 and 9 showed agonistic activity for hPPAR-gamma. Moreover, compound 9 was identified as a PPAR-delta antagonist. These results demonstrate that our virtual screening protocol is able to enrich novel scaffolds for PPAR ligands that could be useful for drug development in the area of atherosclerosis, dyslipidaemia, and type 2 diabetes.

Original language	English
Journal	Journal of Medicinal Chemistry
Volume	51
Issue number	20
Pages (from-to)	6303-6317
Number of pages	14
ISSN	0022-2623
DOIs	https://doi.org/10.1021/jm800128k
Publication status	Published - 2008
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1021/jm800128k

Cite this

Markt, P., Petersen, R. K., Flindt, E. N., Kristiansen, K., Kirchmair, J., Spitzer, G., Distinto, S., Schuster, D., Wolber, G., Laggner, C., & Langer, T. (2008). Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening. Journal of Medicinal Chemistry, 51(20), 6303-6317. https://doi.org/10.1021/jm800128k

Markt, P, Petersen, RK, Flindt, EN, Kristiansen, K, Kirchmair, J, Spitzer, G, Distinto, S, Schuster, D, Wolber, G, Laggner, C & Langer, T 2008, 'Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening', Journal of Medicinal Chemistry, vol. 51, no. 20, pp. 6303-6317. https://doi.org/10.1021/jm800128k

@article{10320510f75411ddbf70000ea68e967b,

title = "Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening",

abstract = "Peroxisome proliferator-activated receptors (PPARs) are important targets for drugs used in the treatment of atherosclerosis, dyslipidaemia, obesity, type 2 diabetes, and other diseases caused by abnormal regulation of the glucose and lipid metabolism. We applied a virtual screening workflow based on a combination of pharmacophore modeling with 3D shape and electrostatic similarity screening techniques to discover novel scaffolds for PPAR ligands. From the resulting 10 virtual screening hits, five tested positive in human PPAR ligand-binding domain (hPPAR-LBD) transactivation assays and showed affinities for PPAR in a competitive binding assay. Compounds 5, 7, and 8 were identified as PPAR-alpha agonists, whereas compounds 2 and 9 showed agonistic activity for hPPAR-gamma. Moreover, compound 9 was identified as a PPAR-delta antagonist. These results demonstrate that our virtual screening protocol is able to enrich novel scaffolds for PPAR ligands that could be useful for drug development in the area of atherosclerosis, dyslipidaemia, and type 2 diabetes.",

author = "Patrick Markt and Petersen, {Rasmus K} and Flindt, {Esben N} and Karsten Kristiansen and Johannes Kirchmair and Gudrun Spitzer and Simona Distinto and Daniela Schuster and Gerhard Wolber and Christian Laggner and Thierry Langer",

year = "2008",

doi = "10.1021/jm800128k",

language = "English",

volume = "51",

pages = "6303--6317",

journal = "Journal of Medicinal Chemistry",

issn = "0022-2623",

publisher = "American Chemical Society",

number = "20",

}

TY - JOUR

T1 - Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening

AU - Markt, Patrick

AU - Petersen, Rasmus K

AU - Flindt, Esben N

AU - Kristiansen, Karsten

AU - Kirchmair, Johannes

AU - Spitzer, Gudrun

AU - Distinto, Simona

AU - Schuster, Daniela

AU - Wolber, Gerhard

AU - Laggner, Christian

AU - Langer, Thierry

PY - 2008

Y1 - 2008

N2 - Peroxisome proliferator-activated receptors (PPARs) are important targets for drugs used in the treatment of atherosclerosis, dyslipidaemia, obesity, type 2 diabetes, and other diseases caused by abnormal regulation of the glucose and lipid metabolism. We applied a virtual screening workflow based on a combination of pharmacophore modeling with 3D shape and electrostatic similarity screening techniques to discover novel scaffolds for PPAR ligands. From the resulting 10 virtual screening hits, five tested positive in human PPAR ligand-binding domain (hPPAR-LBD) transactivation assays and showed affinities for PPAR in a competitive binding assay. Compounds 5, 7, and 8 were identified as PPAR-alpha agonists, whereas compounds 2 and 9 showed agonistic activity for hPPAR-gamma. Moreover, compound 9 was identified as a PPAR-delta antagonist. These results demonstrate that our virtual screening protocol is able to enrich novel scaffolds for PPAR ligands that could be useful for drug development in the area of atherosclerosis, dyslipidaemia, and type 2 diabetes.

AB - Peroxisome proliferator-activated receptors (PPARs) are important targets for drugs used in the treatment of atherosclerosis, dyslipidaemia, obesity, type 2 diabetes, and other diseases caused by abnormal regulation of the glucose and lipid metabolism. We applied a virtual screening workflow based on a combination of pharmacophore modeling with 3D shape and electrostatic similarity screening techniques to discover novel scaffolds for PPAR ligands. From the resulting 10 virtual screening hits, five tested positive in human PPAR ligand-binding domain (hPPAR-LBD) transactivation assays and showed affinities for PPAR in a competitive binding assay. Compounds 5, 7, and 8 were identified as PPAR-alpha agonists, whereas compounds 2 and 9 showed agonistic activity for hPPAR-gamma. Moreover, compound 9 was identified as a PPAR-delta antagonist. These results demonstrate that our virtual screening protocol is able to enrich novel scaffolds for PPAR ligands that could be useful for drug development in the area of atherosclerosis, dyslipidaemia, and type 2 diabetes.

U2 - 10.1021/jm800128k

DO - 10.1021/jm800128k

M3 - Journal article

C2 - 18821746

SN - 0022-2623

VL - 51

SP - 6303

EP - 6317

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

IS - 20

ER -

Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this